Follow us on Twitter
twitter icon@FreshPatents


Major Histocompatibility Complex patents

      

This page is updated frequently with new Major Histocompatibility Complex-related patent applications.




 Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides patent thumbnailCleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides
In one aspect, the disclosure relates to major histocompatibility complex (mhc) molecules comprising a ligand in the peptide binding groove of the mhc molecule, whereby the ligand comprises an azobenzene (abc), and at least two amino acid residues separated by the azo-group of the abc, and wherein the amino acid residues are positioned to interact with the peptide binding groove of the mhc molecule. The disclosure also relates, among others, to means and methods for producing and using such mhc molecules, and the ligands therefor..
Technische Universität München


 Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers patent thumbnailNovel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


 Medicament for use in a  inducing or extending a cellular cytotoxic immune response patent thumbnailMedicament for use in a inducing or extending a cellular cytotoxic immune response
The present invention relates to a medicament for use in a method of extending a cellular cytotoxic immune response against an antigen-comprising protein, the method comprising the step of: i) administering to a patient having t cells activated against an antigen a peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell and an adjuvant which supports a th-1-mediated response, wherein the peptide is derived from the antigen-comprising protein, thereby re-activating the activated t cell, wherein the peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell of step i) is administered in a time frame of from 0 h to 14 days after the t cells were activated against an antigen.. .
Bundesrepublik Deutschland Ietzvertreten Durch Das Robert Koch-institut Vertreten Durch Seinen Präsi


 Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers patent thumbnailNovel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


 A medicament for use in a  inducing or extending a cellular cytotoxic immune response patent thumbnailA medicament for use in a inducing or extending a cellular cytotoxic immune response
The present invention relates to a medicament for use in a method of inducing a cellular cytotoxic immune response, the method comprising the steps of: i) administering to a patient a delivery system comprising (a) a molecule binding to a receptor on the surface of a dendritic cell, (b) an antigen-comprising protein bound to molecule of (a) and (c) a first adjuvant, wherein upon binding of the molecule of (a) to the receptor, the protein of (b) is internalized and processed in the dendritic cell and the antigen comprised in the protein is presented on the surface of the dendritic cell, thereby activating a t cell in the patient; and ii) administering to the patient a re-activator selected from the group consisting of (d) complexed interleukin 2 (il-2cx), (e) a peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell and a second adjuvant, and (f) a combination of (d) and (e), wherein the peptide is derived from the antigen-comprising protein as defined in step i), thereby reactivating the t cell activated in step i), wherein the re-activator of step ii) is administered in a time frame of from 0 h to 14 days after the administration of the delivery system of step i).. .
Bundesrepublik Deutschland Ietztvertreten Durch Da S Robert Koch-institut Vertreten Durch Seinen Prä


 Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications patent thumbnailTransgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted h2 class i gene, a disrupted h2 class ii gene, a functional hla class i transgene, and a functional hla class ii transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both h2 class i and class ii molecules, wherein the transgenic mouse comprises a functional hla class i transgene and a functional hla class ii transgene.
Institut Pasteur


 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers patent thumbnailNovel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers patent thumbnailNovel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers patent thumbnailNovel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


 Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers patent thumbnailNovel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnology Gmbh

Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Peptide sequences and compositions

Wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (mhc) allele, and wherein the polypeptide is not a complete influenza virus protein.. .

Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen

The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a muc1 tumor antigen independently of an major histocompatibility complex (mhc). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a t cell receptor.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma.
Immatics Biotechnologies Gmbh

Method for generating t-cells compatible for allogenic transplantation

The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are characterized in that the expression of beta 2-microglobulin (b2m) and/or class ii major histocompatibility complex transactivator (ciita) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by dna cleavage the gene encoding b2m and/or ciita, or by using nucleic acid molecules which inhibit the expression of b2m and/or ciita.
Cellectis

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Soluble mic neutralizing monoclonal antibody for treating cancer

Disclosed are compositions and methods relating to antibodies that bind soluble major histocompatibility complex class i chain-related (smic). Specifically, disclosed are antibodies designed or selected to inhibit smic (e.g.
University Of Washington Through Its Center For Commercialization

Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Method for treating cancer

The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (mhc), or cancer, characterized by aberrant, misregulated, or increased enhancer of zeste homolog 2 (ezh2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an ezh2 inhibitor.. .
Epizyme, Inc.

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Recombinant t-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction

Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (mhc) molecule including covalently linked first, second, and third domains; wherein the first domain is an mhc class ii β1 domain and the second domain is an mhc class ii α1 domain; or wherein the first domain is an mhc class i α1 domain and the second domain is an mhc class i α2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system..
The United States Government As Represented By The Department Of Veterans Affairs

Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Tumor antigen based on products of the tumor suppressor gene wt1

A tumor antigen that comprises, as an active ingredient, a product of the wilms' tumor suppressor gene wt1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (mhc) class i in said amino acid sequence, and a vaccine comprising said antigen.. .
International Institute Of Cancer Immunology, Inc.

Major histocompatability coplex single nucleotide polymorphisms

The present disclosure relates to the identification of single nucleotide polymorphisms (snps) in the gamma genomic block in the central region of the major histocompatibility complex (mhc) that can be used for matching transplant donors and recipients and determining disease susceptibility.. .
Conexio Genomics Pty Ltd

Immunogenic peptides and their use in immune disorders

The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a t-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class ii major histocompatibility complex (mhc) determinant and recognised by cd4+ t cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence.
Katholieke Universiteit Leuven



Major Histocompatibility Complex topics:
  • Histocompatibility
  • Major Histocompatibility Complex
  • Compatibility
  • Immune Response
  • Specificity
  • Antibodies
  • Polypeptide
  • Recombinant
  • Therapeutics
  • Immunostimulator
  • Stimulator
  • Monoclonal Antibody
  • Monoclonal
  • Immunotherapy
  • Nucleic Acid


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Major Histocompatibility Complex for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Major Histocompatibility Complex with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4938

    file did exist - 3465

    2 - 1 - 51